Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eleclazine in Long QT2 Syndrome
NCT02365506Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eleclazine in Long QT syndrome type 2 (LQT2) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Change From Baseline in Standard 12-Lead Electrocardiogram (ECG) Daytime QT Interval Corrected For Heart Rate Using The Fridericia Formula (QTcF) (AUC0-8)/8 at Day 3. Started Jul 2015; status: completed.
02
Drugs
eleclazine
03
Conditions
Long QT syndrome type 2 (LQT2)
Beyond the preview
Go deeper on NCT02365506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365506.